Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Breast Neoplasms 10Stomach Neoplasms 8Prostatic Neoplasms 7Squamous Cell Carcinoma of Head and Neck 4Lung Neoplasms 4Gastrointestinal Neoplasms 3Neoplasms 2Head and Neck Neoplasms 2HER2-positive Breast Cancer 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stage I Prostate Adenocarcinoma AJCC v7 1Squamous Cell Non-small Cell Lung Cancer 1Recurrent Squamous Cell Lung Carcinoma 1Recurrence 1Progression Free Survival 1Pathologic Complete Response 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm Recurrence, Local 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Lymphoid Interstitial Pneumonia 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1HER2-negative Breast Cancer 1FGFR1 Gene Amplification 1

Interventions

Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Squamous Cell Non-small Cell Lung Cancer × Docetaxel × Clear all
NCT06319313 2024-03-20

Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer

Shanghai JMT-Bio Inc.

Phase 2/3 Not yet recruiting
534 enrolled
Thoracic

Squamous Cell Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡